.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,066,869

« Back to Dashboard

Claims for Patent: 9,066,869

Title:Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
Inventor(s): Krishnamurthy; Thinnayam N. (Scarborough, CA), Darke; Andrew (Newmarket, CA)
Assignee: Purdue Pharma (Pickering, Ontario, CA)
Application Number:14/049,677
Patent Claims: 1. An oral controlled release formulation comprising a plurality of multi-layer release beads collectively comprising a dose of methylphenidate, each bead comprising: (i) an outer immediate release layer comprising a portion of the dose of methylphenidate, (ii) a release delaying layer under the outer immediate release layer, the release delaying layer comprising a pH-dependent polymer, (iii) a controlled release layer under the release delaying layer, the controlled release layer comprising a hydrophobic material selected from the group consisting of an alkylcellulose, an acrylic polymer and mixtures thereof; and (iv) an immediate release core under the controlled release layer, the immediate release core comprising a further portion of the dose of methylphenidate, wherein from about 30% to about 40% of the dose of methylphenidate is in the outer immediate release layers of the beads and from about 60% to about 70% of the dose of methylphenidate is in the immediate release cores of the beads, and the formulation provides (a) a time to a maximum plasma concentration of methylphenidate at about 0.5 to about 4 hours after oral administration to a human patient, (b) a plasma concentration of methylphenidate which does not differ by more than 10% during a measuring interval, wherein the measuring interval is from about 6 hours to about 12 hours, and (c) an in-vitro dissolution as follows: TABLE-US-00035 Time % Methylphenidate (hours) Dissolved 0.25 0-45% 1 5-50% 4 40-90% 8 NLT 60% 12 NLT 80%.

2. The formulation of claim 1, wherein the formulation provides a time to maximum plasma concentration at about 0.5 to about 2 hours after oral administration.

3. The formulation of claim 1, wherein about 40% of the dose of methylphenidate is in the outer immediate release layers of the beads and about 60% of the dose of methylphenidate is in the immediate release cores of the beads.

4. The formulation of claim 1, wherein about 30% of the dose of methylphenidate is in the outer immediate release layers of the beads and about 70% of the dose of methylphenidate is in the immediate release cores of the beads.

5. The formulation of claim 1, wherein the plurality of the multi-layer release beads is incorporated into a hard gelatin capsule.

6. The formulation of claim 1, wherein the immediate release core further comprises a spheroid or a bead.

7. The formulation of claim 6, wherein the spheroid or the bead is sprayed with the further portion of the dose of the methylphenidate.

8. The formulation of claim 1, wherein each bead comprises a coat of a barrier agent between the immediate release core and the controlled release layer.

9. The formulation of claim 8, wherein the barrier agent is hydroxypropylmethylcellulose.

10. The formulation of claim 1, wherein the dose is 20 mg.

11. An oral controlled release formulation comprising a plurality of multi-layer release beads collectively comprising a dose of methylphenidate, each bead comprising: (i) an outer immediate release layer comprising a portion of the dose of methylphenidate, (ii) a release delaying layer under the outer immediate release layer, the release delaying layer comprising a pH-dependent polymer, (iii) a controlled release layer under the release delaying layer, the controlled release layer comprising a hydrophobic material selected from the group consisting of an alkylcellulose, an acrylic polymer and mixtures thereof; and (iv) an immediate release core under the controlled release layer, the immediate release core comprising a further portion of the dose of methylphenidate, wherein from about 30% to about 40% of the dose of methylphenidate is in the outer immediate release layers of the beads and from about 60% to about 70% of the dose of methylphenidate is in the immediate release cores of the beads, and the formulation provides (a) a time to a maximum plasma concentration of methylphenidate at about 0.5 to about 2 hours after oral administration to a human patient, (b) a plasma concentration of methylphenidate which does not differ by more than 10% during a measuring interval, wherein the measuring interval is from about 2 hours to about 6 hours, and (c) an in-vitro dissolution as follows: TABLE-US-00036 Time % Methylphenidate (hours) Dissolved 0.25 0-45% 1 5-50% 4 40-90% 8 NLT 60% 12 NLT 80%.

12. The formulation of claim 11, wherein the immediate release core further comprises a spheroid or a bead.

13. The formulation of claim 12, wherein the spheroid or the bead is sprayed with the further portion of the dose of the methylphenidate.

14. The formulation of claim 12, wherein each bead comprises a coat of a barrier agent between the immediate release core and the controlled release layer.

15. The formulation of claim 11, which provides effective plasma levels of methylphenidate for from about 8 to about 10 hours.

16. An oral controlled release formulation comprising a plurality of multi-layer release beads collectively comprising a dose of methylphenidate, each bead comprising: (i) an outer immediate release layer comprising a portion of the dose of methylphenidate, (ii) a release delaying layer under the outer immediate release layer, the release delaying layer comprising a pH-dependent polymer, (iii) a controlled release layer under the release delaying layer, the controlled release layer comprising a hydrophobic material selected from the group consisting of an alkylcellulose, an acrylic polymer and mixtures thereof; and (iv) an immediate release core under the controlled release layer, the immediate release core comprising a further portion of the dose of methylphenidate, wherein from about 30% to about 40% of the dose of methylphenidate is in the outer immediate release layers of the beads and from about 60% to about 70% of the dose of methylphenidate is in the immediate release cores of the beads, and the formulation provides (a) a time to a maximum plasma concentration of methylphenidate at about 0.5 to about 2 hours after oral administration to a human patient, (b) effective plasma levels of methylphenidate for from about 8 to about 10 hours, and (c) an in-vitro dissolution as follows: TABLE-US-00037 Time % Methylphenidate (hours) Dissolved 0.25 0-45% 1 5-50% 4 40-90% 8 NLT 60% 12 NLT 80%.

17. The formulation of claim 16, wherein the immediate release core further comprises a spheroid or a bead.

18. The formulation of claim 17, wherein the spheroid or the bead is sprayed with the further portion of the dose of the methylphenidate.

19. The formulation of claim 16, wherein each bead comprises a coat of a barrier agent between the immediate release core and the controlled release layer.

20. A method of treating Attention Deficit Hyperactivity Disorder in a child comprising: administering to the child once-a-day in the morning a formulation according to claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc